ArticlePLoS neglected tropical diseases2026
Unraveling the cytokine profile in acute Chagas disease in the Brazilian Amazon: Insights before and after treatment.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease (CD) is a neglected anthropozoonosis caused by Trypanosoma cruzi, with the oral route standing out as the primary cause for the increase in acute cases in the Brazilian Amazon and a key factor in the increase of acute cases. Despite this, the immune response in affected individuals remains minimally explored in humans. This longitudinal study aimed to characterize the serum cytokine profile in patients with acute CD before and after treatment. Participants were recruited from several municipalities in the state of Amazonas, and individuals with chronic inflammatory diseases were excluded. The cytokines IL-1α, IL-2, IL-4, IL-5, IL-6, IL-10, IL-17α, TNF-α, and IFN-γ were analyzed. From 2017 to 2022, 35 patients and 14 controls were included (mean age 46.3 ± 17.8 years; 57.1% male; 74.3% from oral transmission outbreaks). Twenty-five patients (71.4%) were successfully followed up, despite logistical challenges. Elevated levels of all cytokines were found in acute-phase patients before treatment, indicating an effective immune activation. After an average of 12 months post-treatment, significant reductions were observed in IL-6 (p < 0.001), TNF-α (p = 0.011), IFN-γ (p < 0.001), and IL-10 (p = 0.015). IL-2 showed strong correlations with IL-1α and IL-17α in the acute phase (r = 0.91 and 0.95). Post-treatment cytokine profiles resembled those of the control group, suggesting treatment efficacy in modulating inflammation. IL-17α, IL-10, and IL-2 maintained an interesting pattern after treatment. Cardiac MRI revealed myocardial injury by late gadolinium enhancement (LGE) in 27.3% of pre-treatment and 33.3% of post-treatment patients. IL-1α, IL-17α, and IL-4 had moderate negative correlations (r = -0.36 to -0.67) with LGE. These results highlight the importance of monitoring the inflammatory response in the long term, as well as the observed cytokine modulation, which reinforces the hypothesis of not only a favorable acute immune response but also a sustained long-term clinical improvement following treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.